Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2006 3
2007 12
2008 25
2009 48
2010 52
2011 51
2012 68
2013 66
2014 88
2015 84
2016 82
2017 69
2018 101
2019 113
2020 136
2021 165
2022 145
2023 18
Text availability
Article attribute
Article type
Publication date

Search Results

1,147 results
Results by year
Filters applied: . Clear all
Page 1
Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.
Townsley DM, Scheinberg P, Winkler T, Desmond R, Dumitriu B, Rios O, Weinstein B, Valdez J, Lotter J, Feng X, Desierto M, Leuva H, Bevans M, Wu C, Larochelle A, Calvo KR, Dunbar CE, Young NS. Townsley DM, et al. N Engl J Med. 2017 Apr 20;376(16):1540-1550. doi: 10.1056/NEJMoa1613878. N Engl J Med. 2017. PMID: 28423296 Free PMC article. Clinical Trial.
We combined standard immunosuppressive therapy with eltrombopag in previously untreated patients with severe aplastic anemia. METHODS: We enrolled 92 consecutive patients in a prospective phase 1-2 study of immunosuppressive therapy plus eltrombopag. The three conse …
We combined standard immunosuppressive therapy with eltrombopag in previously untreated patients with severe aplastic anemia. METHODS …
Eltrombopag for use in children with immune thrombocytopenia.
Kim TO, Despotovic J, Lambert MP. Kim TO, et al. Blood Adv. 2018 Feb 27;2(4):454-461. doi: 10.1182/bloodadvances.2017010660. Blood Adv. 2018. PMID: 29487060 Free PMC article. Review.
Eltrombopag is currently the only US Food and Drug Administration-approved thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia (ITP) in children. ...Long-term safety data in children are limited, and studies in adults have not revealed a cl
Eltrombopag is currently the only US Food and Drug Administration-approved thrombopoietin receptor agonist for the treatment of chron
Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation.
Fattizzo B, Levati G, Cassin R, Barcellini W. Fattizzo B, et al. Drugs. 2019 Aug;79(12):1305-1319. doi: 10.1007/s40265-019-01159-0. Drugs. 2019. PMID: 31292909 Review.
Eltrombopag is an orally available thrombopoietin receptor agonist indicated for the treatment of immune thrombocytopenia (ITP). ...Additional mechanisms of action emerging from the clinical use of eltrombopag include modulation of T-regulatory cells, restoration of
Eltrombopag is an orally available thrombopoietin receptor agonist indicated for the treatment of immune thrombocytopenia (ITP). ...A
Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study.
Wong RSM, Saleh MN, Khelif A, Salama A, Portella MSO, Burgess P, Bussel JB. Wong RSM, et al. Blood. 2017 Dec 7;130(23):2527-2536. doi: 10.1182/blood-2017-04-748707. Epub 2017 Oct 17. Blood. 2017. PMID: 29042367 Free article. Clinical Trial.
In phase 2/3 trials, eltrombopag treatment of 6 months or less in patients with chronic/persistent immune thrombocytopenia (ITP) increased platelet counts and reduced bleeding. The open-label EXTEND study evaluated long-term safety and efficacy of eltrombopag in adu …
In phase 2/3 trials, eltrombopag treatment of 6 months or less in patients with chronic/persistent immune thrombocytopenia (ITP) incr …
Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study.
Patel BA, Groarke EM, Lotter J, Shalhoub R, Gutierrez-Rodrigues F, Rios O, Quinones Raffo D, Wu CO, Young NS. Patel BA, et al. Blood. 2022 Jan 6;139(1):34-43. doi: 10.1182/blood.2021012130. Blood. 2022. PMID: 34525188 Free PMC article. Clinical Trial.
In 2017, our phase 2 trial reported improved hematologic responses with the addition of eltrombopag (EPAG) to standard IST for SAA when compared with a historical cohort treated with IST alone. ...
In 2017, our phase 2 trial reported improved hematologic responses with the addition of eltrombopag (EPAG) to standard IST for SAA wh …
Eltrombopag.
Bussel JB, Pinheiro MP. Bussel JB, et al. Cancer Treat Res. 2011;157:289-303. doi: 10.1007/978-1-4419-7073-2_17. Cancer Treat Res. 2011. PMID: 21052963 Review.
Discovered in the middle of last decade, followed by experiments in mice and then approved in humans, Eltrombopag is the first TPO-r mimetic available. It has been used and validated in several clinical studies in different etiologies of thrombocytopenia, including primary …
Discovered in the middle of last decade, followed by experiments in mice and then approved in humans, Eltrombopag is the first TPO-r …
Activity of eltrombopag in severe aplastic anemia.
Scheinberg P. Scheinberg P. Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):450-456. doi: 10.1182/asheducation-2018.1.450. Hematology Am Soc Hematol Educ Program. 2018. PMID: 30504345 Free PMC article. Review.
The basis for this approval was the observation of single-agent activity of eltrombopag in this patient population, where 40% to 50% recovered blood counts at times involving >1 lineage. ...Longer follow-up will help in define these long-term risks. In this review, the …
The basis for this approval was the observation of single-agent activity of eltrombopag in this patient population, where 40% to 50% …
Eltrombopag in children with severe aplastic anemia.
Lesmana H, Jacobs T, Boals M, Gray N, Lewis S, Ding J, Kang G, Hale M, Weiss M, Reiss U, Wang W, Wlodarski M. Lesmana H, et al. Pediatr Blood Cancer. 2021 Aug;68(8):e29066. doi: 10.1002/pbc.29066. Epub 2021 Apr 15. Pediatr Blood Cancer. 2021. PMID: 33855784
Patients received either standard immunosuppressive therapy (IST-Std) or IST with eltrombopag (IST-Epag). The primary outcome was the objective response (OR), including partial and complete response (CR), at 6 and 12 months after starting therapy. ...Two patients who previ …
Patients received either standard immunosuppressive therapy (IST-Std) or IST with eltrombopag (IST-Epag). The primary outcome was the …
Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia.
Guan Y, Hasipek M, Jiang D, Tiwari AD, Grabowski DR, Pagliuca S, Kongkiatkamon S, Patel B, Singh S, Parker Y, LaFramboise T, Lindner D, Sekeres MA, Mian OY, Saunthararajah Y, Maciejewski JP, Jha BK. Guan Y, et al. J Clin Invest. 2022 Feb 15;132(4):e149856. doi: 10.1172/JCI149856. J Clin Invest. 2022. PMID: 35085104 Free PMC article.
Eltrombopag treatment results in a durable trilineage hematopoietic expansion in patients. Some of the eltrombopag hematopoietic activity has been attributed to its off-target effects, including iron chelation properties. ...
Eltrombopag treatment results in a durable trilineage hematopoietic expansion in patients. Some of the eltrombopag hematopoiet
Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.
Al-Samkari H, Jiang D, Gernsheimer T, Liebman H, Lee S, Wojdyla M, Vredenburg M, Cuker A. Al-Samkari H, et al. Br J Haematol. 2022 May;197(3):359-366. doi: 10.1111/bjh.18081. Epub 2022 Feb 18. Br J Haematol. 2022. PMID: 35179784 Free PMC article.
Limited data are available describing outcomes in patients who switched from romiplostim or eltrombopag to avatrombopag, a newer oral TPO-RA. We performed a retrospective observational study of adults with ITP who switched from eltrombopag or romiplostim to avatromb …
Limited data are available describing outcomes in patients who switched from romiplostim or eltrombopag to avatrombopag, a newer oral …
1,147 results